FDA Blocked Melanoma Drug as Confusion Reigned Under Makary

The FDA's decision to withhold approval of a new skin cancer treatment has been met with criticism from doctors and patients, with some citing concerns about the agency's changed culture under Commissioner Marty Makary. The treatment, called RP1, had shown promise in prolonging the lives of some patients. The FDA's decision has raised questions about the agency's standards and processes.